Estimation of influence and tolerance of inhalations of hypertonic 7 % saline together with hyaluronic acid in chronic nonspecific pulmonary diseases
BACKGROUND. Chronic inflammatory reaction in chronic nonspecific pulmonary diseases leads to the accumulation of sputum in airways, which causes frequent exacerbations and disease progression. Inhalations of 7 % hypertonic saline (HS) is an effective method of sputum removal, however, the majority of patients, which have the determined bronchial hyperreactivity, can’t tolerate such treatment. Addition of 0.1 % hyaluronic acid (HA) increases their tolerance of HS.
OBJECTIVE. The aim of the study was to estimate the influence and tolerance of inhalations of OKISTAR hyal 7 %, containing 7 % HS and sodium hyaluronate (SH) in patients with chronic obstructive pulmonary diseases (COPD).
MATERIALS AND METHODS. We investigated 62 patients with COPD, which produced more than 10 ml of sputum daily and had more than 2 exacerbations annually on the background of adherence to standard therapy. All patients were divided into 3 clinical and pathogenetic groups. Study design was similar to open comparative randomized study.
RESULTS AND DISCUSSION. Antioxidant and membrane-stabilizing action of nebulization of HS and HS + SH was proved by the significant decrease of byproducts and end products of lipid peroxidation in blood, namely, isolated double bonds (IDB), diene conjugates (DC), ketodienes and conjugated trienes (KCT), malone dialdehyde in plasma (MDpl), oxidative modification of neutral and base proteins aldehyde- and ketone-dinitrohydrazones, peroxide resistance of red blood cells (PRRBC) and elimination of factors of misbalance of antioxidant protection, increase of the content of reduced glutathione and ceruloplasmine; decrease of catalase, glutathione transferase, glutathione peroxidase in the dynamics of proposed treatment. Analysis of the research data showed that the level of MApl, IDB, DC, KCT, PRRBC lowered from the baseline values in group 2В by 39.3; 17.3; 16.02; 16.5 and 72.9 % respectively (р<0.05 in all cases). The received data suggest that the proposed addition to basic therapy leads to the normalization of activity balance in the system of antiradical protection. Such effects are clearly seen in case of combined therapy (HS + HA) usage, which certifies the synergic action of proposed medications.
CONCLUSIONS. Usage of OKISTAR hyal 7 %, which contains HS7 % and SH 0.1 %, in patients with COPD exacerbations provides the additional effect due to improvement of functional parameters, decreases the systemic steroids usage and the risk of basic therapy failures, diminishes exacerbation length and duration of inpatient treatment, decreases the need in salbutamol inhalations and dyspnea grade, provides the positive dynamics of clinical symptoms and increases the quality of life. Combination of HS and HA for nebulization is characterized by the synergetic action of both medications and can be administered to patients with COPD, beginning from stage II, as a basic therapy.
Todoriko L.D. Discussion questions on the mechanisms of the development of pathological polymorbidity in chronic obstructive pulmonary diseases in older people. Clinical immunology. Allergology. Infectology. 2013; 5: 41-5.
Wedzicha J.A., Calverley P.M., Rabe K.F. Roflumilast: a review of its use in the treatment of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 81-90.
Feschenko Y.I., Iashyna L.A., Nazarenko K.V., Moskalenko S.M., Opimakh S.G., Musienko N.M. Diagnostics of hyperinflation and emphysema in patients with asthma and COPD overlap on the primary and specialized levels of medical care. Ukr. Pulmonol. J. 2018; 1: 7-13.
Burney P., Jarvis D., Perez-Padilla R. The global burden of chronic respiratory disease in adults. Int. J. Tuberc. Lung Dis. 2015; 19: 10-20.
Todoriko L.D. Pathophysiological reasons for the development of critical conditions in inflammatory lung diseases of various origins. Clinical immunology. Allergology. Infectology. 2016; 1: 18-22.
Barnes P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016; 138 (1): 16-27.
Pertseva T.O., Myhailichenko D.S. Serum level of transforming growth factor-1 in patients with chronic obstructive pulmonary disease and its correlation with clinical and functional indices. Ukr. Pulmonol. J. 2016; 4: 33-36.
Bagdonas E., Raudoniute J., Bruzauskaite I., Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 995-1013.
Dubé B., Guerder A., Morelot-Panzini C., Laveneziana P. The clinical relevance of the emphysema hyperinflated phenotype in COPD. COPD Research and Practice. 2016; 2 (1): 1-11.
Martines-Garcia М., De Gracia J., Relat M. Predicting high risk of exacerbations in bronchiectasis: the E-FACED. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 275-84.
Lee A.L., Burge A.T., Holland A.E. Airway clearance techniques for bronchiectasis. Cochrane Systematic Review – Intervention Version Published: 23 Nov 2015. https://doi.org/10.1002/14651858.CD008351.pub3.
Wilkinson M., Sugumar K., Milan S.J., Hart A., Crockett A., Crossingham I. Mucolytics for bronchiectasis. Cochrane Systematic Review – Interven- tion Version Published: 2 May 2014. https://doi.org/10.1002/14651858. CD001289.pub2.
Kellett F., Robert N. Nebulised 7 % hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 2011; 105: 1831-5.
Müllerova Н., Maselli D., Locantore N., Vestbo J., Hurst J. et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015; 147 (4): 999-1007.
Woodruff P., Agusti A., Roche N., Singh D., Martinez F. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015; 385 (9979): 1789-98.
Lee A.L., Hill C.J., McDonald C.F., Holland A.E. Pulmonary rehabilitation in individuals with non-cystic fibrosis bronchiectasis: a systematic review. Arch. Phys. Med. Rehabil. 2017; 98: 774-8.
This work is licensed under a Creative Commons Attribution 4.0 International License.